We hypothesize that patients with detectable levels of IgM might be more able to clear pathogens via T cell–independent IgM antibody production whereas patients with undetectable levels of IgM cannot clear pathogens as rapidly and thus develop bronchiectasis. The gene discussed is CD40LG; the disease is bronchiectasis.